RCT
Published: Jan 2014
ACE Report #6010
Ace Report Cover Tumour

Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.

Contributing Authors: K Hood R Grieve P Barrett-Lee A Casbard J Abraham R Coleman P Simmonds H Timmins D Wheatley G Griffiths N Murray

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.